Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease

Journal of Neurology

Volumn 260, Issue 10, 2013, Pages 2523-2531

  Böttcher, Tobias ^a   Rolfs, Arndt ^a   Meyer, Bianca ^a   Grossmann, Annette ^a   Berg, Daniela ^b   Kropp, Peter ^a   Benecke, Reiner ^a   Walter, Uwe ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Gaucher disease; GBA mutation; Glucocerebrosidase; Parkinson's disease; Substantia nigra hyperechogenicity

Indexed keywords

GLUCOSYLCERAMIDASE;

ADULT; AGED; ALLELE; ARTICLE; BRAIN STEM; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA SEQUENCE; ECHOENCEPHALOGRAPHY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HYPOSMIA; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA;

ADULT; AGED; BRAIN; DNA MUTATIONAL ANALYSIS; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL; YOUNG ADULT;

EID: 84886092382     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7011-2     Document Type: Article

References (47)

1. Lees AJ, Hardy J, Revesz T (2009) Parkinson's disease. Lancet 373:2055-2066
2. Neudorfer O, Giladi N, Elstein D et al (1996) Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 89:691-694
3. Tayebi N, Callahan M, Madike V et al (2001) Gaucher disease and Parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73:313-321
4. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E (2008) The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 65:1353-1357
5. Tayebi N, Walker J, Stubblefield B et al (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to Parkinsonism? Mol Genet Metab 79:104-109
6. Kraoua I, Stirnemann J, Ribeiro MJ et al (2009) Parkinsonism in Gaucher's disease type 1: ten new cases and a review of the literature. Mov Disord 24:1524-1530
7. Mazzulli JR, Xu YH, Sun Y et al (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37-52
8. Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361:1651-1661
9. Lesage S, Anheim M, Condroyer C et al (2011) Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 20:202-210
10. Gan-Or Z, Giladi N, Rozovski U et al (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70:2277-2283
11. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC (1993) Risk factors for Parkinson's disease. Neurology 43:1693-1697
12. Marder K, Tang MX, Mejia H et al (1996) Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 47:155-160
13. Berg D, Seppi K, Behnke S et al (2013) Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 28:216-219
14. Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7:1044-1055
15. Berg D, Roggendorf W, Schröder U et al (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999-1005
16. Saunders-Pullman R, Hagenah J, Dhawan V et al (2010) Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord 25:1364-1372
17. Brockmann K, Srulijes K, Hauser AK et al (2011) GBA-associated PD presents with nonmotor characteristics. Neurology 77:276-280
18. Barrett MJ, Hagenah J, Dhawan V et al (2013) Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease. Parkinsonism Relat Disord 19:186-191
19. Kresojević N, Mijajlović M, Perić S et al (2013) Transcranial sonography in patients with Parkinson's disease with glucocerebrosidase mutations. Parkinsonism Relat Disord 19:431-435
20. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
21. Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson's disease II, 1st edn. Macmillan, New York, pp 153-163
22. Louis ED, Luchsinger JA, Tang MX, Mayeux R (2003) Parkinsonian signs in older people: prevalence and associations with smoking and coffee. Neurology 61:24-28
23. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561-571
24. Hummel T, Konnerth CG, Rosenheim K, Kobal G (2001) Screening of olfactory function with a four-minute odor identification test: reliability, normative data, and investigations in patients with olfactory loss. Ann Otol Rhinol Laryngol 110:976-981
25. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480-1491
26. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
27. Reitan RM (1958) The validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 8:271-276
28. Busse K, Heilmann R, Kleinschmidt S et al (2012) Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson's disease. J Neurol Neurosurg Psychiatry 83:441-447
29. Weiβ RH (1998) Grundintelligenztest Skala 2 (CFT 20), 4th edn. Hogrefe, Göttingen
30. Tewes U (1997) Der Hamburg-Wechsler-Intelligenztest für Erwachsene, 2nd edn. Hogrefe, Göttingen
31. Brickenkamp R (2002) Test d2-Aufmerksamkeits-Belastungs-Test. Hogrefe, Göttingen
32. Benton AL (1974) The Revised Visual Retention Test, 4th edn. Psychological Corp., New York
33. Vymazal J, Righini A, Brooks RA et al (1999) T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211:489-495
34. Seeman PJ, Finckh U, Höppner J et al (1996) Two new missense mutations in a non-Jewish Caucasian family with type 3 Gaucher disease. Neurology 46:1102-1107
35. Koprivica V, Stone DL, Park JK et al (2000) Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 66:1777-1786
36. Beutler E, Gelbart T, Scott CR (2005) Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 35:355-364
37. Grabowski GA (2005) Recent clinical progress in Gaucher disease. Curr Opin Pediatr 17:519-524
38. McNeill A, Duran R, Proukakis C et al (2012) Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord 27:526-532
39. Behnke S, Schroeder U, Dillmann U et al (2009) Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 47:1237-1243
40. Walter U, Wagner S, Horowski S, Benecke R, Zettl UK (2009) Transcranial brain sonography findings predict disease progression in multiple sclerosis. Neurology 73:1010-1017
41. Stein P, Yu H, Jain D, Mistry PK (2010) Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol 85:472-476
42. Mekinian A, Stirnemann J, Belmatoug N et al (2012) Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment. Blood Cells Mol Dis 49:53-57
43. Hagenah J, König IR, Sperner J et al (2010) Life-long increase of substantia nigra hyperechogenicity in transcranial sonography. Neuroimage 51:28-32
44. Bultron G, Kacena K, Pearson D et al (2010) The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis 33:167-173
45. Barrett MJ, Giraldo P, Capablo JL et al (2013) Greater risk of Parkinsonism associated with non-N370S GBA1 mutations. J Inherit Metab Dis 36:575-580
46. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E (2010) Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol 120:641-649
47. Cullen V, Sardi SP, Ng J et al (2011) Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol 69:940-953